Appointment of Nominated Adviser and Sole Broker

Avacta Group PLC

11 June 2024

 

11 June 2024

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Appointment of Nominated Adviser and Sole Broker

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces the appointment of Peel Hunt LLP as its Nominated Adviser and sole broker with immediate effect.

-Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director	Tel: [phone] www.avacta.com
Peel Hunt LLP (Nomad and Sole Broker) James Steel / Chris Golden / Patrick Birkholm	Tel: [phone] www.peelhunt.com
ICR Consilium (Media and IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji	[e-mail]

About Avacta Group plc - https://www.avacta.com

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta has two divisions: A clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division focused on supporting healthcare professionals.

Avacta has two proprietary platforms, pre|CISION™ and Affimer^®.

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is highly upregulated in most solid tumours compared with healthy tissues. The pre|CISION^TM platform harnesses this tumour specific protease to activate pre|CISION^TM peptide drug conjugates and pre|CISION^TM antibody drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability compared with standard doxorubicin and preliminary signs of clinical activity.

Affimer^® is a novel biologic platform which has significant technical and commercial advantages compared with antibodies and can be used both to develop advanced immunotherapies and to improve the performance of immunodiagnostics.

To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/

 

END